Free tool
FAERS Monitor: Orladeyo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214094 or its brand name (Orladeyo, Berotralstat Dihydrochloride). Reports on generic versions are filed under their own applications.
Reports
911
Serious
434
48% of reports
Hospitalization
214
Death reported
28
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hereditary angioedema258
- nausea63
- diarrhoea62
- drug ineffective61
- headache56
- abdominal pain52
- gastrointestinal disorder50
- condition aggravated47
- fatigue44
- vomiting40
- malaise37
- abdominal pain upper36
- covid-1936
- dizziness32
- injection site pain31
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 70 |
| 2022 | 86 |
| 2023 | 105 |
| 2024 | 201 |
| 2025 | 308 |
| 2026 | 135 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,248 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hereditary angioedemaSignal | 258 | 568.7 | 512.0 | 142,220 |
| gastrointestinal disorderSignal | 50 | 12.9 | 9.8 | 539 |
| abdominal painSignal | 52 | 5.2 | 4.0 | 172 |
| covid-19Signal | 36 | 4.7 | 3.4 | 103 |
| abdominal pain upperSignal | 36 | 4.0 | 2.9 | 80 |
| condition aggravatedSignal | 47 | 3.6 | 2.7 | 86 |
| injection site painSignal | 31 | 2.3 | 1.7 | 23 |
| diarrhoeaSignal | 62 | 2.2 | 1.7 | 42 |
| headacheSignal | 56 | 2.1 | 1.6 | 30 |
| vomiting | 40 | 2.0 | 1.5 | 18 |
| malaise | 37 | 1.9 | 1.4 | 16 |
| nausea | 63 | 1.8 | 1.4 | 24 |
| dizziness | 32 | 1.5 | 1.1 | 5 |
| fatigue | 44 | 1.3 | 1.0 | 3 |
| drug ineffective | 61 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.